NCJ Number
251161
Date Published
August 2017
Length
88 pages
Annotation
This report presents the numbers, provisions, status, and date of last action for Federal and each State's legislation as of 2017 that pertains to the establishment, responsibilities, and operations of State Prescription Drug Monitoring Programs (PDMPs).
Abstract
At the Federal level, HR 993 was referred to the House Subcommittee on Health in February 2017. This bill, if enacted, would create the Opioid Abuse Prevention and Treatment Act of 2017. It provides that the Secretary of Health and Human Services award grants to one or more States to perform a 1-year pilot project to develop a standardized peer review process and methodology to review and evaluate prescriber and pharmacy dispensing patterns through a review of the State PDMP in the States receiving grants. It further provides that grantee States must make PDMP data available to State regulators and licensing boards regarding those controlled substances for which a prescriber is required to be registered with the Drug Enforcement Administration and may make such information available to State regulators. Federal HR 1854 was referred to the House Subcommittee on Crime, Terrorism, Homeland Security, and Investigations. It would create the "Prescription Drug Monitoring Act of 2017." This bill pertains to requirements for States receiving grant funds under the Harold Rogers grant program or the controlled substance monitoring program of the Public Health Services Act. Federal SB 778, which is the U.S. Senate version of HR 1854, was referred to the Senate Committee on Health, Education, Labor, and Pensions in March 2017. Information on the aforementioned Federal legislation is followed by a review of each State's legislation pertinent to the establishment, responsibilities, and operations of the State's PDMP.